Super-responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres

J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1321-e1322. doi: 10.1111/jdv.19310. Epub 2023 Jul 13.

Authors

M Menéndez Sánchez¹, A Muñiz de Lucas¹, E Pérez Fernández², M Llamas Velasco³, D P Ruiz Genao¹, J L López Estébaranz¹

Affiliations

¹ Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
² Department of Preventive Medicine, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
³ Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain.

PMID: 37415564
DOI: 10.1111/jdv.19310

No abstract available

Publication types

Letter

MeSH terms

Etanercept
Humans
Interleukin-23*
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Interleukin-23
Etanercept